Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707351 | 0.85 | ADORA3 (0.69) | ADORA3KMT2AMAPTLMNANPC1 | |
| SCHEMBL16697304 | 0.74 | ADORA3 (0.53) | ADORA3MAPTALDH1A1NPC1NPSR1 | |
| SCHEMBL3882170 | 0.72 | RXFP1 (0.52) | RXFP1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL16707354 | 0.68 | MAPT (0.49) | ADORA3MAPTNPC1NPSR1RAB9A | |
| SCHEMBL16707357 | 0.68 | MAPT (0.64) | ADORA3KMT2AMAPTNPC1NPSR1 | |
| SCHEMBL16697602 | 0.68 | ADORA3 (0.82) | ADORA3MAPTALDH1A1LMNAHPGD | |
| SCHEMBL13734246 | 0.67 | GPBAR1 (0.61) | KMT2AMAPTALDH1A1LMNANPC1 | |
| SCHEMBL16697810 | 0.67 | NPC1 (0.55) | ADORA3MAPTALDH1A1NPC1NPSR1 | |
| SCHEMBL642821 | 0.65 | CES2 (0.56) | KMT2AMAPTALDH1A1 | |
| SCHEMBL31011141 | 0.65 | CES2 (0.56) | KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | ADORA3 2615/4885RXFP1 3443/4885KMT2A 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.